Hospital Center of Périgueux   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Périgueux France (1953)

Organization Overview

First Clinical Trial
2019
NCT04113226
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

CH de Perigueux | CH Périgueux

Active Ingredients

Drugs in Phase 3 Trials (1)

dalbavancin (dalvance) (1 trial)

Drugs in Phase 2 Trials (2)

lenalidomide (revlimid) (1 trial)

rituximab (rituxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3